Format

Send to

Choose Destination
Int J Dev Neurosci. 2011 Oct;29(6):583-91. doi: 10.1016/j.ijdevneu.2010.12.007. Epub 2011 Jan 28.

Erythropoietin for neonatal brain injury: opportunity and challenge.

Author information

1
Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.

Abstract

Neonatal brain injury, caused by perinatal hypoxia-ischemia and extreme prematurity, remains a great challenge for prevention and treatment. There is no effective treatment for term hypoxic-ischemic encephalopathy (HIE) except hypothermia which by itself does not afford complete neuroprotection. Erythropoietin (EPO), a pleiotropic cytokine, has neuroprotective effects in a series of neonatal experimental models and recent clinical trials of HIE. However, the mechanisms, dosing, and the toxicity of EPO in these settings are inconsistently reported. This review will focus on the possible mechanisms, recent clinical advances and potential complications of EPO used in research and the clinic. In addition, optimal dose and administrative routes of EPO, and novel EPO mimetics will be discussed.

PMID:
21277366
DOI:
10.1016/j.ijdevneu.2010.12.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center